000249930 001__ 249930
000249930 005__ 20240221115049.0
000249930 0247_ $$2doi$$a10.1093/braincomms/fcad005
000249930 0247_ $$2pmid$$apmid:36744011
000249930 0247_ $$2pmc$$apmc:PMC9893225
000249930 0247_ $$2altmetric$$aaltmetric:142209319
000249930 037__ $$aDZNE-2023-00245
000249930 041__ $$aEnglish
000249930 082__ $$a610
000249930 1001_ $$0P:(DE-2719)2814088$$aGriffin, Jarred$$b0$$eFirst author
000249930 245__ $$aRehabilitation enhances epothilone-induced locomotor recovery after spinal cord injury.
000249930 260__ $$a[Großbritannien]$$bGuarantors of Brain$$c2023
000249930 3367_ $$2DRIVER$$aarticle
000249930 3367_ $$2DataCite$$aOutput Types/Journal article
000249930 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1708440613_6810
000249930 3367_ $$2BibTeX$$aARTICLE
000249930 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000249930 3367_ $$00$$2EndNote$$aJournal Article
000249930 520__ $$aMicrotubule stabilization through epothilones is a promising preclinical therapy for functional recovery following spinal cord injury that stimulates axon regeneration, reduces growth-inhibitory molecule deposition and promotes functional improvements. Rehabilitation therapy is the only clinically validated approach to promote functional improvements following spinal cord injury. However, whether microtubule stabilization can augment the beneficial effects of rehabilitation therapy or act in concert with it to further promote repair remains unknown. Here, we investigated the pharmacokinetic, histological and functional efficacies of epothilone D, epothilone B and ixabepilone alone or in combination with rehabilitation following a moderate contusive spinal cord injury. Pharmacokinetic analysis revealed that ixabepilone only weakly crossed the blood-brain barrier and was subsequently excluded from further investigations. In contrast, epothilones B and D rapidly distributed to CNS compartments displaying similar profiles after either subcutaneous or intraperitoneal injections. Following injury and subcutaneous administration of epothilone B or D, rats were subjected to 7 weeks of sequential bipedal and quadrupedal training. For all outcome measures, epothilone B was efficacious compared with epothilone D. Specifically, epothilone B decreased fibrotic scaring which was associated with a retention of fibronectin localized to perivascular cells in sections distal to the lesion. This corresponded to a decreased number of cells present within the intralesional space, resulting in less axons within the lesion. Instead, epothilone B increased serotonergic fibre regeneration and vesicular glutamate transporter 1 expression caudal to the lesion, which was not affected by rehabilitation. Multiparametric behavioural analyses consisting of open-field locomotor scoring, horizontal ladder, catwalk gait analysis and hindlimb kinematics revealed that rehabilitation and epothilone B both improved several aspects of locomotion. Specifically, rehabilitation improved open-field locomotor and ladder scores, as well as improving the gait parameters of limb coupling, limb support, stride length and limb speed; epothilone B improved these same gait parameters but also hindlimb kinematic profiles. Functional improvements by epothilone B and rehabilitation acted complementarily on gait parameters leading to an enhanced recovery in the combination group. As a result, principal component analysis of gait showed the greatest improvement in the epothilone B plus rehabilitation group. Thus, these results support the combination of epothilone B with rehabilitation in a clinical setting.
000249930 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x0
000249930 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000249930 650_7 $$2Other$$aaxon regeneration
000249930 650_7 $$2Other$$aepothilone
000249930 650_7 $$2Other$$aneuroplasticity
000249930 650_7 $$2Other$$arehabilitation
000249930 650_7 $$2Other$$aspinal cord injury
000249930 7001_ $$aHingorani Jai Prakash, Sonia$$b1
000249930 7001_ $$aBockemühl, Till$$b2
000249930 7001_ $$0P:(DE-2719)9002577$$aBenner, Jessica M$$b3$$udzne
000249930 7001_ $$0P:(DE-2719)2811123$$aSchaffran, Barbara$$b4
000249930 7001_ $$00000-0002-6035-9491$$aMoreno-Manzano, Victoria$$b5
000249930 7001_ $$aBüschges, Ansgar$$b6
000249930 7001_ $$0P:(DE-2719)2810270$$aBradke, Frank$$b7$$eLast author
000249930 773__ $$0PERI:(DE-600)3020013-1$$a10.1093/braincomms/fcad005$$gVol. 5, no. 1, p. fcad005$$n1$$pfcad005$$tBrain communications$$v5$$x2632-1297$$y2023
000249930 8564_ $$uhttps://academic.oup.com/braincomms/article/5/1/fcad005/6987086
000249930 8564_ $$uhttps://pub.dzne.de/record/249930/files/DZNE-2023-00245.pdf$$yOpenAccess
000249930 8564_ $$uhttps://pub.dzne.de/record/249930/files/DZNE-2023-00245.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000249930 909CO $$ooai:pub.dzne.de:249930$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000249930 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814088$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000249930 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002577$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000249930 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811123$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000249930 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810270$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000249930 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x0
000249930 9141_ $$y2023
000249930 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000249930 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000249930 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2023-08-24
000249930 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN COMMUN : 2022$$d2023-08-24
000249930 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-02-21T13:34:18Z
000249930 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-02-21T13:34:18Z
000249930 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000249930 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000249930 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-24
000249930 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000249930 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2022-02-21T13:34:18Z
000249930 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-24
000249930 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000249930 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-24
000249930 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-24
000249930 9201_ $$0I:(DE-2719)1013002$$kAG Bradke$$lAxon Growth and Regeneration$$x0
000249930 980__ $$ajournal
000249930 980__ $$aVDB
000249930 980__ $$aUNRESTRICTED
000249930 980__ $$aI:(DE-2719)1013002
000249930 9801_ $$aFullTexts